The Board has remanded the claims for ischemic heart disease and neuropathy due to exposure to herbicide agents, as no such exposure is established. The Veteran's current diagnoses are at least as likely as not caused by Agent Orange exposure during service.
The deciding factor: The VA examination did not provide an opinion regarding direct service connection without resorting to speculation.
- Claimed conditions
- Ischemic heart disease, Neuropathy
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- None in this decision
- Decision date
- October 7, 2020
- Citation
- 20065390
What this means for you
A remand is not a loss. The Board sent the case back for more development — often a new exam or missing records — before making a final decision. Many remands later end in a grant, and the decision spells out exactly what the Board wanted to see.
What you can do next
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Granted
The Veteran is granted special monthly compensation (SMC) at the R(1) rate due to his need for regular aid and attendance.
- Dismissed
The Veteran withdrew his appeals for increased ratings of ischemic heart disease and diabetes, and these claims are dismissed.
- Partly granted
The Board granted service connection for diabetes mellitus type II, ischemic heart disease, and hypertension from August 10, 2022, under the PACT Act. The claim for a thyroid disability was denied.
- Remanded (sent back)
The Board remands the case to request a medical opinion on whether service-connected hypertension or ischemic heart disease was a principal or contributory cause of the Veteran's death.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.